254 related articles for article (PubMed ID: 29279511)
1. IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma.
Kishi S; Minato M; Saijo A; Murakami N; Tamaki M; Matsuura M; Murakami T; Nagai K; Abe H; Nishioka Y; Doi T
Intern Med; 2018 May; 57(9):1259-1263. PubMed ID: 29279511
[TBL] [Abstract][Full Text] [Related]
2. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
[TBL] [Abstract][Full Text] [Related]
3. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
4. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
5. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of Advanced or Postoperative Recurrent Non-small Lung Cancer Cases Treated with Nivolumab].
Ichiki Y; Iwanami T; Kakizoe K; Hamatsu T; Suehiro T; Yoneda K; Tanaka F; Sugimachi K
J UOEH; 2017; 39(4):291-297. PubMed ID: 29249742
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
[TBL] [Abstract][Full Text] [Related]
8. Relapsed Myasthenia Gravis after Nivolumab Treatment.
Mitsune A; Yanagisawa S; Fukuhara T; Miyauchi E; Morita M; Ono M; Tojo Y; Ichinose M
Intern Med; 2018 Jul; 57(13):1893-1897. PubMed ID: 29434145
[TBL] [Abstract][Full Text] [Related]
9. IgA nephropathy after pembrolizumab therapy for mesothelioma.
Wang R; Das T; Takou A
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257374
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report.
Chen YH; Liu FC; Hsu CH; Chian CF
Medicine (Baltimore); 2017 Jul; 96(27):e7350. PubMed ID: 28682883
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.
Lim JS; Soo RA
Ther Adv Respir Dis; 2016 Oct; 10(5):444-54. PubMed ID: 27480166
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report.
Daanen RA; Maas RJH; Koornstra RHT; Steenbergen EJ; van Herpen CML; Willemsen AECAB
J Immunother; 2017; 40(9):345-348. PubMed ID: 28961608
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-associated acute glomerulonephritis: a case report and literature review.
Jung K; Zeng X; Bilusic M
BMC Nephrol; 2016 Nov; 17(1):188. PubMed ID: 27876011
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
Feng Y; Wang X; Bajaj G; Agrawal S; Bello A; Lestini B; Finckenstein FG; Park JS; Roy A
Clin Cancer Res; 2017 Sep; 23(18):5394-5405. PubMed ID: 28916617
[No Abstract] [Full Text] [Related]
15. Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis.
Kudo F; Watanabe Y; Iwai Y; Miwa C; Nagai Y; Ota H; Yabe H; Demitsu T; Hagiwara K; Koyama N; Koyama S
Intern Med; 2018 Aug; 57(15):2217-2221. PubMed ID: 29526968
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].
Imai Y; Tanaka M; Fujii R; Uchitani K; Okazaki K
Yakugaku Zasshi; 2019; 139(3):491-495. PubMed ID: 30828027
[TBL] [Abstract][Full Text] [Related]
17. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.
Kawakami H; Tanizaki J; Tanaka K; Haratani K; Hayashi H; Takeda M; Kamata K; Takenaka M; Kimura M; Chikugo T; Sato T; Kudo M; Ito A; Nakagawa K
Invest New Drugs; 2017 Aug; 35(4):529-536. PubMed ID: 28317087
[TBL] [Abstract][Full Text] [Related]
18. Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma.
Irifuku T; Satoh A; Tani H; Mandai K; Masaki T
CEN Case Rep; 2020 Feb; 9(1):48-54. PubMed ID: 31605271
[TBL] [Abstract][Full Text] [Related]
19. Aprepitant for refractory nivolumab-induced pruritus.
Ito J; Fujimoto D; Nakamura A; Nagano T; Uehara K; Imai Y; Tomii K
Lung Cancer; 2017 Jul; 109():58-61. PubMed ID: 28577951
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]